Perspective Therapeutics Inc. (CATX)vsEdwards Lifesciences Corp (EW)
CATX
Perspective Therapeutics Inc.
$2.94
-2.00%
HEALTHCARE · Cap: $336.44M
EW
Edwards Lifesciences Corp
$88.97
-0.70%
HEALTHCARE · Cap: $49.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1053670% more annual revenue ($6.51B vs $618,000). EW leads profitability with a 15.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).
CATX
Avoid30
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CATX.
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$88.97
$169.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : CATX
The strongest argument for CATX centers on Price/Book, Debt/Equity.
Bull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : CATX
The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
CATX profiles as a value stock while EW is a mature play — different risk/reward profiles.
CATX carries more volatility with a beta of 1.75 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (-21M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 30/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Perspective Therapeutics Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?